Protagonist Therapeutics (PTGX) stock broke out Monday after the company's Johnson & Johnson (JNJ)-partnered drug topped its rival from Bristol Myers Squibb (BMY) in a study of plaque psoriasis patients.
↑ X NOW PLAYING How To Buy Stocks: Spotting Early Entries On Potential BreakoutsProtagonist and J&J pitted their experimental drug, icotrokinra or JNJ-2113, against Bristol's approved treatment, Sotyktu. In addition to showing statistically significant results on the primary goals of the study — improvement in inflammation and reaching clear skin — icotrokinra outperformed Sotyktu across all study goals at weeks 16 and 24.
Now, J&J is planning a head-to-head study comparing the same drug in patients to its own Stelara in patients with plaque psoriasis. This suggests "JNJ's strong confidence in JNJ-2113's efficacy as well as commitment to establishing JNJ-2113 as a paradigm shifting therapy in PsO, and potentially additional indications as well," Wedbush analyst Yun Zhong said in a report.
Protagonist Therapeutics shares shot up more than 30% to 50.03 in early action. Shares opened north of a buy point at 48.89 out of a consolidation, according to MarketSurge.
More to follow.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.
Why Moderna Stock Has Surged 15% This Week Despite Mixed News
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists
Get Timely Buy & Sell Alerts With IBD Leaderboard
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.